Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Washington
With
PRIMARY OBJECTIVES: I. Evaluate the response of sunitinib (sunitinib malate) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria in patients with recurrent/metastatic iodine refractory well differentiated thyroid carcinoma (WDTC) or medullary thyroid carcinoma (MTC). SECONDARY OBJECTIVES: I. Evaluate early positron emission tomography (PET) changes in patients with WDTC and MTC treated with sunitinib. II. Determine the safety and toxicity of sunitinib given as a continuous treatment in patients with WDTC and MTC. III. Evaluate the effect of sunitinib therapy on overall survival, duration of response and time-to-progression. IV. Evaluate serial tumor markers, thyroglobulin (WDTC) or calcitonin (MTC), during therapy. These measurements will not be used to define disease progression or response. V. Correlate changes in serial tumor markers with radiologic response. OUTLINE: Patients receive sunitinib malate orally (PO) once daily (QD). Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then for 2 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted